RALEIGH, N.C.—iCare USA’s parent company, Revenio (REG1V:OMHX), has announced its acquisition of Oculo, an Australian company dedicated to telehealth, remote patient monitoring, and clinical communications. The terms of the transaction were not disclosed. With this acquisition, iCare is taking a major step forward in the rapidly growing areas of eye-related telehealth and technology-enhanced eyecare, the company said in a statement. iCare eye diagnostic solutions include intraocular pressure measuring devices, fundus imaging devices and perimeters for diagnosing and monitoring glaucoma and retinal disease pathology.

Oculo's software platform lets doctors communicate and exchange clinical correspondence—such as patient referrals—securely and instantly, enabling faster, more efficient patient care. The software can also transfer clinical data and images in a secure and HIPAA-compliant way, replacing fax communications.
 
iCare Oculo's telemedicine feature enables clinicians to arrange high-quality, secure video consultations from wherever there is internet. The iCare Oculo platform bridges data silos in health care by allowing doctors to share valuable patient information such as imaging, test results, and referrals instantly and securely, regardless of location or EMR.

"We are excited about this acquisition and the opportunity to improve eyecare around the world together," said Dr. Kate Taylor, co-founder and former CEO of Oculo, now director of iCare’s eyecare solutions division. "By facilitating seamless communication among doctors and providing a virtual platform for interaction between eyecare providers and their patients, we can help deliver better outcomes to patients."

iCare USA Inc. is part of Revenio Group, a leading company in ophthalmological devices and software solutions based in Finland.